Cardiovascular outcomes and safety with antidiabetic drugs

about

Cardiovascular outcomes and safety with antidiabetic drugs

Item

http://www.wikidata.org/entity/Q57164250

description

wetenschappelijk artikel

@nl

name

Cardiovascular outcomes and safety with antidiabetic drugs

@en

Cardiovascular outcomes and safety with antidiabetic drugs

@nl

type

Item

label

Cardiovascular outcomes and safety with antidiabetic drugs

@en

Cardiovascular outcomes and safety with antidiabetic drugs

@nl

prefLabel

Cardiovascular outcomes and safety with antidiabetic drugs

@en

Cardiovascular outcomes and safety with antidiabetic drugs

@nl

P1476

Cardiovascular outcomes and safety with antidiabetic drugs

@en

P2093

Khaled K Aldossari

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials

P304

70-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P698

30202411

http://www.w3.org/2001/XMLSchema#string

P932

6124835

http://www.w3.org/2001/XMLSchema#string

Cardiovascular outcomes and safety with antidiabetic drugs

about

Cardiovascular outcomes and safety with antidiabetic drugs

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P698

P932